Zusammenfassung
Interventionell-radiologische Verfahren zur Behandlung von primären und sekundären pulmonalen Malignomen gewinnen zunehmend an Bedeutung. Neben thermisch abladierenden Verfahren ermöglicht die selektive Instillation von Zytostatika und Embolisaten über vaskuläre Zugänge eine lokal begrenzte Therapie. Die Therapien kommen für Patienten, bei denen ein reduzierter Allgemeinzustand keine systemische Chemotherapie zulässt, palliativ in Betracht. Bei funktionell inoperablen Patienten sind insbesondere die ablativen Verfahren eine potenziell kurative Alternative zur Operation. Dieser Artikel soll eine Übersicht über die derzeit angewandten interventionell-radiologischen Verfahren in der pneumologischen Onkologie und ihren Stellenwert geben. Ob die aufgrund ihres günstigen Risiko-Nutzen-Verhältnisses vielversprechenden interventionell-radiologischen Verfahren möglicherweise eine Alternative zur strahlentherapeutischen Behandlung darstellen oder in multimodalen Konzepten überlegen sind, müssen Studien zeigen.
Abstract
Interventional radiological procedures for the treatment of primary and secondary pulmonary malignancies have become increasingly important. In addition to thermally ablative treatment, selective chemoembolisation by a vascular access allows localised therapy. These treatments are considered to be palliative for patients in a reduced general condition which does not allow systemic chemotherapy. In functionally inoperable patients especially the ablative procedures are potentially curative alternatives to surgery. This article provides an overview of the currently used interventional radiological procedures in lung oncology and assesses their importance. Further studies are needed to show whether interventional radiological procedures, which are promising due to their favourable risk–benefit ratio, may represent an alternative to radiotherapy or be effective in multimodal approaches.
Literatur
1
Goeckenjan G, Sitter H, Thomas M et al.
Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin und die Deutsche Krebsgesellschaft. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms.
Pneumologie.
2010;
64 (Suppl 2)
1-164
2
Bach P B, Cramer L D, Warren J L et al.
Racial differences in the treatment of early-stage lung cancer.
N Engl J Med.
1999;
341
1198-1205
3
The International Registry of Lung Metastases .
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.
J Thorac Cardiovasc Surg.
1997;
113
37-49
4
Nordenström B E.
Electrochemical treatment of cancer. I: Variable response to anodic and cathodic fields.
Am J Clin Oncol.
1989;
12
530-536
5
Gillams A R, Lees W R.
Analysis of the factors associated with radiofrequency ablation-induced pneumothorax.
Clin Radiol.
2007;
62
639-644
6
Hoffmann R T, Jakobs T F, Muacevic A et al.
Interventionelle Onkologie bei Lungentumoren.
Radiologe.
2007;
47
1109-1116
7
Sano Y, Kanazawa S, Gobara H et al.
Feasibility of percutaneous radiofrequency ablation for intrathoracic malignancies: a large single-center experience.
Cancer.
2007;
109
1397-1405
8
Abbas G, Pennathur A, Landreneau R J, Luketich J D.
Radiofrequency and microwave ablation of lung tumors.
J Surg Oncol.
2009;
100
645-650
9
Wang H, Littrup P J, Duan Y et al.
Thoracic masses treated with percutaneous cryotherapy: initial experience with more than 200 procedures.
Radiology.
2005;
235
289-298
10
Kawamura M, Izumi Y, Tsukada N et al.
Percutaneous cryoablation of small pulmonary malignant tumors under computed tomographic guidance with local anesthesia for nonsurgical candidates.
J Thorac Cardiovasc Surg.
2006;
131
1007-1013
11
Ritz J P, Lehmann K S, Mols A et al.
Laser-induced thermotherapy for lung tissue – evaluation of two different internally cooled application systems for clinical use.
Lasers Med Sci.
2008;
23
195-202
12
Rosenberg C, Puls R, Hegenscheid K et al.
Laser ablation of metastatic lesions of the lung: long-term outcome.
AJR Am J Roentgenol.
2009;
192
785-792
13
Lencioni R.
Loco-regional treatment of hepatocellular carcinoma.
Hepatology.
2010;
52
762-773
14
Vogl T J, Lehnert T, Zangos S et al.
Transpulmonary chemoembolization (TPCE) as a treatment for unresectable lung metastases.
Eur Radiol.
2008;
18
2449-2455
15
Nakanishi M, Demura Y, Umeda Y et al.
Multi-arterial infusion chemotherapy for non-small cell lung carcinoma – significance of detecting feeding arteries and tumor staining.
Lung Cancer.
2008;
61
227-234
16
Pua B B, Thornton R H, Solomon S B.
Ablation of pulmonary malignancy: current status.
J Vasc Interv Radiol.
2010;
21
223-232
17
Zemlyak A, Moore W H, Bilfinger T V.
Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer.
J Am Coll Surg.
2010;
211
68-72
18
Lencioni R, Crocetti L, Cioni R et al.
Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study).
Lancet Oncol.
2008;
9
621-628
19
Wolf F J, Grand D J, Machan J T et al.
Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients.
Radiology.
2008;
247
871-879
20
Skonieczki B D, Wells C, Wasser E J et al.
Radiofrequency and microwave tumor ablation in patients with implanted cardiac devices: Is it safe?.
Eur J Radiol.
2010;
[Epub ahead of print]
21
van Raemdonck D, Friedel G.
The European Society of Thoracic Surgeons lung metastasectomy project.
J Thorac Oncol.
2010;
5 (6 Suppl 2)
127-129
22
Hiraki T, Gobata H, Mimura H. et al .
Does tumor type affect local control by radiofrequency ablation in the lungs?.
Eur J Radiol.
2010;
74
136-141
Dr. med. Dirk Frechen
Medizinische Klinik I Universitätsklinikum der RWTH Aachen
Pauwelsstr. 30 52057 Aachen
eMail: dfrechen@ukaachen.de